186 related articles for article (PubMed ID: 38169867)
1. Non-glycosylated G protein with CpG ODN provides robust protection against respiratory syncytial virus without inducing eosinophilia.
Kawahara E; Shibata T; Hirai T; Yoshioka Y
Front Immunol; 2023; 14():1282016. PubMed ID: 38169867
[TBL] [Abstract][Full Text] [Related]
2. CpG ODN enhances the efficacy of F protein vaccine against respiratory syncytial virus infection in the upper respiratory tract via CD4
Kawahara E; Yamamoto S; Shibata T; Hirai T; Yoshioka Y
Biochem Biophys Res Commun; 2023 Dec; 686():149143. PubMed ID: 37926041
[TBL] [Abstract][Full Text] [Related]
3. Enhanced immune responses and protection by vaccination with respiratory syncytial virus fusion protein formulated with CpG oligodeoxynucleotide and innate defense regulator peptide in polyphosphazene microparticles.
Garlapati S; Garg R; Brownlie R; Latimer L; Simko E; Hancock RE; Babiuk LA; Gerdts V; Potter A; van Drunen Littel-van den Hurk S
Vaccine; 2012 Jul; 30(35):5206-14. PubMed ID: 22713718
[TBL] [Abstract][Full Text] [Related]
4. A Built-In CpG Adjuvant in RSV F Protein DNA Vaccine Drives a Th1 Polarized and Enhanced Protective Immune Response.
Ma Y; Jiao YY; Yu YZ; Jiang N; Hua Y; Zhang XJ; Fu YH; Peng XL; Zheng YP; Anderson LJ; He JS
Viruses; 2018 Jan; 10(1):. PubMed ID: 29342954
[TBL] [Abstract][Full Text] [Related]
5. A unique combination adjuvant modulates immune responses preventing vaccine-enhanced pulmonary histopathology after a single dose vaccination with fusion protein and challenge with respiratory syncytial virus.
Lee Y; Ko EJ; Kim KH; Lee YT; Hwang HS; Kwon YM; Graham BS; Kang SM
Virology; 2019 Aug; 534():1-13. PubMed ID: 31163351
[TBL] [Abstract][Full Text] [Related]
6. Immunization with Low Doses of Recombinant Postfusion or Prefusion Respiratory Syncytial Virus F Primes for Vaccine-Enhanced Disease in the Cotton Rat Model Independently of the Presence of a Th1-Biasing (GLA-SE) or Th2-Biasing (Alum) Adjuvant.
Schneider-Ohrum K; Cayatte C; Bennett AS; Rajani GM; McTamney P; Nacel K; Hostetler L; Cheng L; Ren K; O'Day T; Prince GA; McCarthy MP
J Virol; 2017 Apr; 91(8):. PubMed ID: 28148790
[TBL] [Abstract][Full Text] [Related]
7. A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge.
Wang D; Phan S; DiStefano DJ; Citron MP; Callahan CL; Indrawati L; Dubey SA; Heidecker GJ; Govindarajan D; Liang X; He B; Espeseth AS
J Virol; 2017 Jun; 91(11):. PubMed ID: 28298602
[TBL] [Abstract][Full Text] [Related]
8. Virus-like particle vaccines containing F or F and G proteins confer protection against respiratory syncytial virus without pulmonary inflammation in cotton rats.
Hwang HS; Kim KH; Lee Y; Lee YT; Ko EJ; Park S; Lee JS; Lee BC; Kwon YM; Moore ML; Kang SM
Hum Vaccin Immunother; 2017 May; 13(5):1031-1039. PubMed ID: 28129031
[TBL] [Abstract][Full Text] [Related]
9. Virus-Like Particle Vaccine Containing the F Protein of Respiratory Syncytial Virus Confers Protection without Pulmonary Disease by Modulating Specific Subsets of Dendritic Cells and Effector T Cells.
Kim KH; Lee YT; Hwang HS; Kwon YM; Kim MC; Ko EJ; Lee JS; Lee Y; Kang SM
J Virol; 2015 Nov; 89(22):11692-705. PubMed ID: 26355098
[TBL] [Abstract][Full Text] [Related]
10. RSV recombinant candidate vaccine G1F/M2 with CpG as an adjuvant prevents vaccine-associated lung inflammation, which may be associated with the appropriate types of immune memory in spleens and lungs.
Li N; Zhang L; Zheng B; Li W; Liu J; Zhang H; Zeng R
Hum Vaccin Immunother; 2019; 15(11):2684-2694. PubMed ID: 31021703
[TBL] [Abstract][Full Text] [Related]
11. Long-Lasting Protection Induced by a Polyanhydride Nanovaccine against Respiratory Syncytial Virus in an Outbred Mouse Model.
Stephens LM; Ross KA; McLellan JS; Narasimhan B; Varga SM
J Virol; 2022 Nov; 96(22):e0150222. PubMed ID: 36314826
[TBL] [Abstract][Full Text] [Related]
12. Nonglycosylated G-Protein Vaccine Protects against Homologous and Heterologous Respiratory Syncytial Virus (RSV) Challenge, while Glycosylated G Enhances RSV Lung Pathology and Cytokine Levels.
Fuentes S; Coyle EM; Golding H; Khurana S
J Virol; 2015 Aug; 89(16):8193-205. PubMed ID: 26018164
[TBL] [Abstract][Full Text] [Related]
13. Additive protection induced by mixed virus-like particles presenting respiratory syncytial virus fusion or attachment glycoproteins.
Lee S; Quan FS; Kwon Y; Sakamoto K; Kang SM; Compans RW; Moore ML
Antiviral Res; 2014 Nov; 111():129-35. PubMed ID: 25239522
[TBL] [Abstract][Full Text] [Related]
14. Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge.
Gilbert BE; Patel N; Lu H; Liu Y; Guebre-Xabier M; Piedra PA; Glenn G; Ellingsworth L; Smith G
Vaccine; 2018 Dec; 36(52):8069-8078. PubMed ID: 30389195
[TBL] [Abstract][Full Text] [Related]
15. Alternative Virus-Like Particle-Associated Prefusion F Proteins as Maternal Vaccines for Respiratory Syncytial Virus.
Blanco JCG; Fernando LR; Zhang W; Kamali A; Boukhvalova MS; McGinnes-Cullen L; Morrison TG
J Virol; 2019 Dec; 93(23):. PubMed ID: 31511382
[TBL] [Abstract][Full Text] [Related]
16. Delta inulin-derived adjuvants that elicit Th1 phenotype following vaccination reduces respiratory syncytial virus lung titers without a reduction in lung immunopathology.
Wong TM; Petrovsky N; Bissel SJ; Wiley CA; Ross TM
Hum Vaccin Immunother; 2016 Aug; 12(8):2096-2105. PubMed ID: 27215855
[TBL] [Abstract][Full Text] [Related]
17. Prefusion RSV F Immunization Elicits Th2-Mediated Lung Pathology in Mice When Formulated With a Th2 (but Not a Th1/Th2-Balanced) Adjuvant Despite Complete Viral Protection.
Eichinger KM; Kosanovich JL; Gidwani SV; Zomback A; Lipp MA; Perkins TN; Oury TD; Petrovsky N; Marshall CP; Yondola MA; Empey KM
Front Immunol; 2020; 11():1673. PubMed ID: 32849580
[TBL] [Abstract][Full Text] [Related]
18. CpG containing oligodeoxynucleotides are potent adjuvants for parenteral vaccination with the fusion (F) protein of respiratory syncytial virus (RSV).
Hancock GE; Heers KM; Smith JD; Scheuer CA; Ibraghimov AR; Pryharski KS
Vaccine; 2001 Sep; 19(32):4874-82. PubMed ID: 11535341
[TBL] [Abstract][Full Text] [Related]
19. Formulation of bovine respiratory syncytial virus fusion protein with CpG oligodeoxynucleotide, cationic host defence peptide and polyphosphazene enhances humoral and cellular responses and induces a protective type 1 immune response in mice.
Kovacs-Nolan J; Mapletoft JW; Lawman Z; Babiuk LA; van Drunen Littel-van den Hurk S
J Gen Virol; 2009 Aug; 90(Pt 8):1892-1905. PubMed ID: 19386785
[TBL] [Abstract][Full Text] [Related]
20. The efficacy of inactivated split respiratory syncytial virus as a vaccine candidate and the effects of novel combination adjuvants.
Lee Y; Ko EJ; Kim KH; Lee YT; Hwang HS; Jung YJ; Jeeva S; Kwon YM; Seong BL; Kang SM
Antiviral Res; 2019 Aug; 168():100-108. PubMed ID: 31150678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
